Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

BMC Gastroenterology

Seungbong Han¹  Jin Mo Yang²  Joo Hyun Sohn³  Chun Kyon Lee⁵  Jeong Won Jang^1,15  Young Min Park^1,10  June Sung Lee⁷  Sung Won Cho^1,14  Jae Youn Cheong^1,14  Hyung Joon Yim^1,16  Kyu Sung Rim^1,13  Seong Gyu Hwang^1,13  Ju Hyun Kim^1,11  Yun Soo Kim^1,11  Sook-Hyang Jeong⁴  Young Seok Kim⁸  Choong Kee Park⁹  Sang Hoon Park⁶  Jung il Lee^1,12  Jin-Woo Lee^1,17  Young-Joo Jin^1,12 

[1] Department of Biostatistics and Clinical Epidemiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;Department of Internal Medicine, St.Vincent Hospital, The Catholic University College of Medicine, Suwon, Republic of Korea;Department of Internal Medicine, Guri Hospital, Hanyang University College of Medicine, Guri, South Korea;Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea;Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Goyang, Suwon, Republic of Korea;Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea;Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, South Korea;Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea;Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea;Department of Internal Medicine, Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, South Korea;Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea;Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea;Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea;Department of Internal Medicine, Ajou University School of Medicine, Suwon, South Korea;Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Incheon, South Korea;Department of Internal Medicine, Korea University College of Medicine, Ansan, South Korea;Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, 27 Inhang-ro, Jung-gu, Incheon,, 400-711, South Korea

关键词: Sustained virological response;    Ribavirin;    Pegylated interferon alfa-2b;    Pegylated interferon alfa-2a;    Chronic hepatitis C;   

Others  :  858025
DOI  :  10.1186/1471-230X-13-74

 received in 2012-12-14, accepted in 2013-04-22,  发布年份 2013

【 摘 要 】

Background

Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).

Methods

This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800–1200 mg/day) for 24 or 48 weeks according to HCV genotypes.

Results

Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×10⁵ and >7×10⁵), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.

Conclusions

Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

【 授权许可】

   
2013 Jin et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Williams R: Global challenges in liver disease. Hepatology 2006, 44:521-526.
• [2]McCaughan GW, Omata M, Amarapurkar D: Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007, 22:615-633.
• [3]Perz JF, Armstrong GL, Farrington LA: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
• [4]Kim WR: The burden of hepatitis C in the United States. Hepatology 2002, 36:S30-S34.
• [5]Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
• [6]EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 2011, 55:245-264.
• [7]Manns MP, McHutchison JG, Gordon SC: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
• [8]Fried MW, Shiffman ML, Reddy KR: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
• [9]Silva M, Poo J, Wagner F: A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006, 45:204-213.
• [10]Bruno R, Sacchi P, Scagnolari C: Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007, 26:369-376.
• [11]McHutchison JG, Lawitz EJ, Shiffman ML: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
• [12]Laguno M, Cifuentes C, Murillas J: Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009, 49:22-31.
• [13]Ascione A, De Luca M, Tartaglione MT: Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology 2010, 138:116-122.
• [14]Rumi MG, Aghemo A, Prati GM: Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010, 138:108-115.
• [15]Awad T, Thorlund K, Hauser G: Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010, 51:1176-1184.
• [16]Yu ML, Chuang WL: Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009, 24:336-345.
• [17]Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
• [18]McHutchison JG, Manns M, Patel K: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
• [19]Miyase S, Haraoka K, Ouchida Y: Randomized trial of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol 2012.
• [20]Zhao S, Liu E, Yu H: Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C. Hepatogastroenterology 2008, 55:1047-1054.
• [21]Lee S, Kim IH, Kim SH: Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 2010, 53:146-153.
• [22]Fujino T, Nakamuta M, Aoyagi Y: Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. Med Sci Monit 2011, 17:CR687-691.
• [23]Ge D, Fellay J, Thompson AJ: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
• [24]Yu ML, Huang CF, Huang JF: Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53:7-13.
• [25]Thomas DL, Thio CL, Martin MP: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
• [26]Jensen DM, Morgan TR, Marcellin P: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-960.
• [27]Poordad F, McCone J Jr, Bacon BR: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
• [28]Jacobson IM, McHutchison JG, Dusheiko G: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
• [29]Ferenci P: Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004, 24(Suppl 2):25-31.
• [30]Ferenci P, Fried MW, Shiffman ML: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425-433.
• [31]Hadziyannis SJ, Sette H Jr, Morgan TR: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
• [32]Maynard M, Pradat P, Gagnieu MC: Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008, 13:607-611.
• [33]Shiffman ML, Ghany MG, Morgan TR: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103-112.